The startup develops liquid biopsy technology that enables non-invasive cancer testing by isolating and analyzing circulating extracellular vesicles and exosomes from cell-free specimens like urine, saliva, and plasma. This method provides healthcare professionals with precise diagnostic information for therapeutic decision-making without the need for invasive procedures.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of disease diagnosis often rely on invasive procedures to obtain tissue samples. Analyzing extracellular vesicles (EVs) and exosomes, which contain crucial biomarkers, requires complex purification steps, limiting throughput and increasing costs.
Solution
WellSIM Biomedical Technologies offers ExoDot, a technology for analyzing exosome surface markers at single-particle resolution directly from biofluids, such as plasma, urine, saliva, and CSF, eliminating the need for purification. This approach enables highly sensitive characterization of various biosamples with enhanced throughput and reduced cost. The platform utilizes customizable capture antibodies and biomarker panels tailored for specific applications in diagnostics, therapeutics, and biological studies. By examining EV-derived biomarkers like DNA, RNA, protein, and lipid profiles, the technology facilitates the detection and diagnosis of diseases, including cancers, neurodegenerative, and autoimmune diseases.
Target Audience
The primary audience includes researchers and clinicians in diagnostics, therapeutics, and biological studies focused on biomarker discovery, disease diagnosis, and targeted drug delivery.
Features
- Detects protein markers of extracellular vesicles at single-particle resolution
- No purification or enrichment required
- Compatible with various biosamples (plasma, culture medium, urine, saliva, and CSF)
- Customizable capture antibodies and biomarker panels
- Multiplex biomarker profiling
- High-throughput and scalable characterization of vesicles
- Quantification of surface markers at superior sensitivity